Ocumetics Technology Corp · TSXV:OTC
Ocumetics Technology — Investor Presentation (March 2025)
36 slides from Ocumetics Technology's investor presentation, March 2025
Slide 1: Always In Focus
Always In Focus Ocumetics Technology Corp. Investor Presentation 2025
Slide 2: Disclaimer
DISCLAIMER Nothing contained in this presentation is or shall be relied upon as a promise, guarantee, representation of or warranty specific or implied as to future performance of Ocumetics Technology Corp. The forward-looking statements contained in this presentation are expressly qualified in thei
Slide 3: Company Highlights
COMPANY HIGHLIGHTS BACKGROUND OCUMETICS LENS • A Canadian research and product development company • An accommodating intraocular lens (IOL). that specializes in adaptive intraocular lens designs. • Natural lens is replaced with the Ocumetics Lens. • 15 years of research to develop the Ocumetics Len
Slide 4: The human eye is a marvel of nature.
The human eye is a marvel of nature.
Slide 5: How the Eye Works
HOW THE EYE WORKS HOW LIGHT ENTERS THE EYE ACCOMMODATION REFRACTIVE ERRORS CATARACTS Myopia Hyperopia LEARN MORE LEARN MORE LEARN MORE LEARN MORE LEARN MORE Light rays enter the eye through the Accommodation is the ability of the eye Refractive error means that the shape of A cataract is when your e
Slide 6: Current vision correction treatments have limitations.
Current vision correction treatments have limitations.
Slide 7: The Problem: Eyesight Deterioration
THE PROBLEM EYESIGHT DETERIORATION • The eye deteriorates as we age. The natural lens hardens, loses flexibility and can become cloudy. This leads to eye disorders including presbyopia and cataracts. • At any one time 2.2 billion people or 29% of the global population requires corrective lenses.2 •
Slide 8: LASIK and PRK Are Imperfect Treatments
LASIK AND PRK ARE IMPERFECT TREATMENTS LASIK EYE SURGERY PHOTOREFRACTIVE KERATECTOMY (PRK) Corneal flap is surgically cut Laser reshapes cornea Outer corneal layer removed Laser reshapes cornea open and folded back. depending on condition. completely. depending on condition. LASIK and PRK are imperf
Slide 9: Intraocular Lenses (IOLs)
INTRAOCULAR LENSES (IOLs) INTRAOCULAR LENSES (IOL) Removal of natural lens. Synthetic lens inserted into Current IOL options lens capsule. LEARN MORE include Monofocal and Multifocal IOLs. An Intraocular Lens is an artificial lens that replaces the focusing power of the natural lens that is surgical
Slide 10: Limitations with Intraocular Lenses (IOLs)
LIMITATIONS WITH INTRAOCULAR LENSES (IOLs) MONOFOCAL IOL MULTIFOCAL IOL Current Monofocal LEARN MORE LEARN MORE and Multifocal IOL Monofocal IOLs provide clear vision at Multifocal IOLs provide clear vision at options have numerous one distance. near and far distances. limitations. LIMITATIONS LIMIT
Slide 11: The Solution: Accommodating IOLs
THE SOLUTION: ACCOMMODATING IOLs ACCOMMODATING IOL Accommodating IOLs are the future of vision LEARN MORE correction surgery. Accommodating IOLs change shape like the eye’s natural lens, facilitating clear vision at various distances. ABOUT ACCOMMODATING IOLs • Accommodating IOLs can move or change
Slide 12: Imagine a world without the need for corrective lenses.
Imagine a world without the need for corrective lenses.
Slide 13: Introducing the Ocumetics Lens
INTRODUCING THE OCUMETICS LENS Ocumetics Technology Corp. Investor Presentation 2025 13
Slide 14: Ocumetics Lens
OCUMETICS LENS An accommodating IOL designed to replicate natural lens CLEAR VISION AT FREEDOM FROM GLASSES FACILITATES FUTURE ALL DISTANCES AND CONTACTS ENHANCEMENTS functionality and Experience the design benefits of clear vision at Imagine waking up every morning with outstanding The Ocumetics Le
Slide 15: How It Works
HOW IT WORKS HOW IT WORKS DESIGN SPECIFICATIONS • The Ocumetics Lens suspension system consists of cushions • A unique design element of the Ocumetics Lens proprietary that are designed to self-customize and conform to the suspension system is the ease for near point focus and unique parameters of e
Slide 16: Components
COMPONENTS CILIARY CONNECTION Uses natural kinetics of the eye’s ciliary GLARE ABSORPTION muscles and zonules to adjust lens. The lens retainer is specially designed to minimize glare and halos. LENS RETAINER SUSPENSION SYSTEM A docking station for the lens that LENS CAPSULE facilitates future lens
Slide 17: Procedure
PROCEDURE OCUMETICS LENS PROCEDURE Removal of natural lens. Retainer inserted into the lens Ocumetics lens inserted into Ocumetics lens and retainer capsule. lens capsule. resting in the lens capsule. LEARN MORE SUITABLE FOR ALL 30 MINUTES MINIMALLY INVASIVE PRESCRIPTIONS The Ocumetics Lens procedur
Slide 18: Market Applications
MARKET APPLICATIONS 1 2 3 The Ocumetics lens has immediate market CATARACT GENERAL VISION FUTURE EMPHASIS CORRECTION DEVELOPMENTS relevancy and immense future potential. The initial focus for the Ocumetics Lens is to become the lens of choice for cataract lens Once established in the market, the Ocu
Slide 19: Our vision is to enhance lives, globally.
Our vision is to enhance lives, globally.
Slide 20: Target Market
TARGET MARKET TARGET MARKET MARKET GROWTH DRIVERS • Accommodating intraocular lens market segment. • Aging population and rising income levels. The market for • Individuals over 55 requiring lens replacement due to cataracts. • Increasing number of cataract surgeries. • Middle class or above. • Incr
Slide 21: Global Market Size
GLOBAL MARKET SIZE $158 BILLION Global eyewear market (2021) in USD. 13 24 MILLION Annual global cataract surgeries (2020). 14 The Ocumetics Lens has global market $6.4 BILLION potential. Projected intraocular lens segment by 2030 in USD. 15 4.9% Intraocular lens segment projected cumulative annual
Slide 22: Business Model
BUSINESS MODEL MANUFACTURING DISTRIBUTION RETAIL (CLINIC) Low cost mass Global sales Product sales and production. initiative. procedures. Outsourced production Production Direct Indirect Product Procedure facility sales sales Sales Ocumetics will outsource Direct sales to ophthalmologists Sales man
Slide 23: Ocumetics aims to become a leader in the accommodating IOL segment.
Ocumetics aims to become a leader in the accommodating IOL segment.
Slide 24: The Competition
THE COMPETITION ATIA17 LUMINA18 The absence of • Shape-changing, fluid filled based with fixed-power • Modular, two-piece IOL. anterior optic for target refraction. commercially available • Hydrophilic acrylic material. • FIH clinical data 2023. • Sulcus-fixated haptics. accommodating IOLs highlight
Slide 25: Strong partnerships for a strong business.
Strong partnerships for a strong business.
Slide 26: Partners
PARTNERS AMIPLANT GMBH Advisor and intraocular lens manufacturer Tooling design and manufacturer Bioana Prototype lens design and manufacturer CRC Clinical Research Consultants Inc. Regulatory advisors Medicil Supplier of intraocular lens injection systems NuSil Avantar Supplier of the silicon in fa
Slide 27: Patents & Regulatory
PATENTS & REGULATORY REGISTRATIONS • Filed with The World International Patent Office (WIPO). • Application for the Inflatable Lens/Lens Retainer registered on Aug 13, 2007. • Two supplemental submissions registered on Nov 5, 2007 and May 7, 2008. • Patent applications were examined for Novelty, Inv
Slide 28: A clear path to success.
ocumetics A clear path to success.
Slide 29: Roadmap
ROADMAP • Begin multi-center pivotal clinical trial Phase 2 • Regulatory submission (Latin America) • Begin first-in-human (FIH) clinical trial • FDA pre-PMA submission • Receive preliminary feedback from FIH clinical trial • ISO 13485 audit (Europe and Canada) • FDA IDE submission • FDA PMA submiss
Slide 30: Leadership on all fronts.
Leadership on all fronts.
Slide 31: Management Team
MANAGEMENT TEAM DEAN E. BURNS BSc DR. GARTH WEBB PRESIDENT, CEO & DIRECTOR FOUNDER, CSO & DIRECTOR • Business executive, scientist and medical device brand marketing • Founder of Ocumetics with a mission to empower people to see expert with over 38 years of healthcare experience, including 27 and be
Slide 32: Management Team
MANAGEMENT TEAM DR. DOYLE STULTING ROGER JEWETT CA, CPA CMO & DIRECTOR CFO & DIRECTOR • Director of the Stulting Research Center, Woolfson Eye Institute, • Hands-on executive with 25+ years of experience leading public and Atlanta, GA. private companies through corporate restructurings, financings a
Slide 33: Board of Directors
BOARD OF DIRECTORS DR. JAMES BARTON MCROBERTS O.D. DAYTON MARKS ROBERT QUINN MICHAEL L EDWARDS CPA (CA), CLU DIRECTOR DIRECTOR DIRECTOR DIRECTOR • Received Doctorate in Optometry from the University of Waterloo • Director, Bonanza Mining Corporation. • Independent businessman with years of diverse •
Slide 34: Investment Details
INVESTMENT DETAILS CAP TABLE (Q1 2025) OTC.V: STOCK PERFORMANCE COMMON SHARES OUTSTANDING 119,767,979 0.40 OPTIONS 9,615,800 0.38 RESTRICTED SHARE UNITS 5,000,000 0.36 WARRANTS 2,317,605 CONVERTIBLE DEBENTURES 12,500,000 0.34 TOTAL SHARES, FULLY DILUTED 149,201,384 0.32 NOTES 0.30 • Completed RTO tr
Slide 35: Contact Us
CONTACT US DEAN E. BURNS PRESIDENT, CEO & DIRECTOR (817) 874-7564 dean.burns@ocumetics.com Learn more at ocumetics.com is listed on the TSX:V, Frankfurt Stock Exchange and OTCQB Ocumetics Technology Corp. Investor Presentation 2025 35
Slide 36: References
REFERENCES 1. National Eye Institute. (2023). Cataracts. nei.nih.gov 2. World Health Organization. (2021). Blindness and vision impairment. who.int 3. Holden, B. A., Fricke, T. R., Wilson, D. A., Jong, M., Naidoo, K. S., Sankaridurg, P., ... & Resnikoff, S. (2016). Global prevalence of myopia and hi
Ocumetics Technology — Investor Presentation (March 2025) on 6ix